The antianginal effect of molsidomine in prolonged oral therapy. A double blind, crossover, randomized study.
A double blind, crossover, random assignment study was undertaken in two 1-monthly stages following aw one-week wash-our period. Cyclo-ergometric tests were used to evaluate the antianginal effects of molsidomine compared with a placebo administered to 5 ambulatory patients with stable angina pectoris. After oral molsidomine (3 x 2 mg/day) the improvement of the evaluated parameters was significant: maximal exercise capacity, total workload, S-T segment depression. The therapeutic superiority of molsidomine compared to placebo is statistically significant. The effectiveness and tolerance observed in this clinical trial confirm the conclusions of numerous investigators.
D000787:Angina Pectoris / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008981:Molsidomine; D010069:Oxadiazoles / Q000627:therapeutic use*; D011897:Random Allocation; D013558:Sydnones / Q000627:therapeutic use*
D010069:Oxadiazoles; D013558:Sydnones; D008981:Molsidomine